Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C
Authors:
- Angela CostantinoACAngela Costantino
- Enea SpadaESEnea Spada
- Michele EquestreMEMichele Equestre
- Roberto BruniRBRoberto Bruni
- Elena TritarelliETElena Tritarelli
- Nicola CoppolaNCNicola Coppola
- Caterina SagnelliCaterina Sagnelli
- Evangelista SagnelliESEvangelista Sagnelli
- Anna Rita CiccaglioneACAnna Rita Ciccaglione
Open Access
- 14 November 2015
- journal article
- research article
- Published by Springer Nature in Virology Journal
- Vol. 12 (1) , 1-5
Abstract
The detection of baseline resistance mutations to new direct-acting antivirals (DAAs) in HCV chronically infected treatment-naïve patients could be important for their management and outcome prevision. In this study, we investigated the presence of mutations, which have been previously reported to be associated with resistance to DAAs in HCV polymerase (NS5B) and HCV protease (NS3) regions, in sera of treatment-naïve patients. HCV RNA from 152 naïve patients (84 % Italian and 16 % immigrants from various countries) infected with different HCV genotypes (21,1a; 21, 1b; 2, 2a; 60, 2c; 22, 3a; 25, 4d and 1, 4k) was evaluated for sequence analysis. Amplification and sequencing of fragments in the NS5B (nt 8256–8640) and NS3 (nt 3420–3960) regions of HCV genome were carried out for 152 and 28 patients, respectively. The polymorphism C316N/H in NS5B region, associated with resistance to sofosbuvir, was detected in 9 of the 21 (43 %) analysed sequences from genotype 1b-infected patients. Naturally occurring mutations V36L, and M175L in the NS3 protease region were observed in 100 % of patients infected with subtype 2c and 4. A relevant proportion of treatment naïve genotype 1b infected patients evaluated in this study harboured N316 polymorphism and might poorly respond to sofosbuvir treatment. As sofosbuvir has been approved for treatment of HCV chronic infection in USA and Europe including Italy, pre-treatment testing for N316 polymorphism on genotype 1b naïve patients should be considered for this drug.Keywords
Funding Information
- Italian Ministry of Health (National Centre for Disease Prevention and Control, Fasc. 3M58)
This publication has 30 references indexed in Scilit:
- Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patientsVirology Journal, 2013
- Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patientsVirology Journal, 2012
- Hepatitis C virus genotype 4d in Southern Italy: Reconstruction of its origin and spread by a phylodynamic analysisJournal of Medical Virology, 2012
- Genotype and Subtype Profiling of PSI-7977 as a Nucleotide Inhibitor of Hepatitis C VirusAntimicrobial Agents and Chemotherapy, 2012
- NS3 Protease Polymorphism and Natural Resistance to Protease Inhibitors in French Patients Infected with HCV Genotypes 1–5Antiviral Therapy, 2011
- Evolving epidemiology of hepatitis C virusClinical Microbiology and Infection, 2011
- In Vitro Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435Antimicrobial Agents and Chemotherapy, 2010
- Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patientsHepatology, 2008
- Changing Epidemiology of HCV and HBV Infections in Northern ItalyJournal of Clinical Gastroenterology, 2008
- Telaprevir and pegylated interferon–alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patientsHepatology, 2007